Mazdutide

Research Phase

Mazdutide (IBI362)

Aliases
IBI362
Administration
Subcutaneous injection

Timing

A general projection of what people report noticing over time, based on the known mechanism and reported use patterns. It is not a guarantee and individual experience varies considerably.

  1. 1

    1–2 Weeks

    Appetite reduction is typically the first noticeable change, consistent with its GLP-1 receptor activity.

  2. 2

    3–4 Weeks

    Fullness after smaller meals tends to become more consistent as the dose is titrated.

  3. 3

    5–7 Weeks

    Early, gradual weight changes may begin to be noticed.

  4. 4

    8–10 Weeks

    Continued appetite and weight changes are typical through this period.

  5. 5

    11–15 Weeks

    Sustained weight loss trends are generally reported through this window in available data.

  6. 6

    16–20 Weeks

    This stage is commonly described as when body composition changes become clearly visible.

  7. 7

    21–24 Weeks

    Many users in markets where it's approved are approaching a maintenance phase by this stage.

⚠️ Research context only. This is not medical advice and results are not guaranteed.